Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have received an average rating of “Moderate Buy” from the six research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $5.77.

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research report on Friday, September 13th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Assenagon Asset Management S.A. lifted its position in shares of CytomX Therapeutics by 206.0% in the second quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company’s stock valued at $1,511,000 after acquiring an additional 833,825 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in CytomX Therapeutics in the 1st quarter worth approximately $124,000. Acadian Asset Management LLC grew its holdings in CytomX Therapeutics by 1.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,690,830 shares of the biotechnology company’s stock valued at $5,863,000 after buying an additional 44,640 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of CytomX Therapeutics during the first quarter valued at approximately $57,000. Finally, Candriam S.C.A. purchased a new position in shares of CytomX Therapeutics in the second quarter worth $256,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Stock Performance

Shares of NASDAQ:CTMX opened at $1.05 on Thursday. The stock’s 50-day simple moving average is $1.15 and its two-hundred day simple moving average is $1.50. The stock has a market capitalization of $82.02 million, a price-to-earnings ratio of 7.50 and a beta of 1.04. CytomX Therapeutics has a 52-week low of $0.99 and a 52-week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). CytomX Therapeutics had a negative return on equity of 27.44% and a net margin of 9.27%. The business had revenue of $25.12 million during the quarter, compared to analysts’ expectations of $21.79 million. During the same period in the previous year, the business posted ($0.02) EPS. As a group, equities analysts forecast that CytomX Therapeutics will post -0.29 earnings per share for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.